Sagaram Uday Shanker
Maruthi Rheumatology Research Center, India
Title: Sjogrens syndrome and Hyperlipoproteinemia (a) A detrimental association
Biography
Biography: Sagaram Uday Shanker
Abstract
INTRODUCTION:
In my 30 years of experience in the field of Cardiology and Rheumatology, I have come across several cases of Dyslipidemia, Hyperlipoprotienemia (a) and inflammatory arthritis. Dyslipidemia not responding to regular treatment with statins, were investigated further and found to have higher levels of lipoprotein (a) which is detrimental to the arthritis patients. On further investigations, few patients were found to have an uncommon combination of Sjogrens syndrome and hyperlipoprotienemia. Such association may lead to sudden / early death. :
OBJECTIVE: Identification of the Association of Hyperlipoprotienemia (a) with Sjogrens syndrome and Vasculitis in autoimmune arthritis diseases.:
METHOD USED: Clinical OP basis: Identified seven cases of Inflammatory arthritis like RA, SLE, MCTD, Enteropathic Arthritis, Psoriatic Arthritis etc. and their association with Hyperlipoprotienemia (a) and associated Sjogrens syndrome ( period 2009 –2015 ):
MEDICAL TREATMENT: - Inflammatory arthritis – DEMARDS and Deflazacort - Hyperlipoprotienemia (a) - Niacin NF 1 gm. per day and Omega fatty acids 500mg per day - Associated dyslipidemias - Statins - Associated diabetes (if required) - Oral Hypoglycemics - Associated hypothyroidism (if required) - Thyroxine tablets
RESULT: Sjogrens syndrome: There was symptomatic relief, such as correction of Dryness of Oral Cavity, Dyspepsia Retroorbital pain, Preauricular Glandular enlargement, lubricant eye drops to dry Palpebrae
- Lipoprotein (a) levels reduced to optimum values in 3 to 6 months:
CONCLUSION:Though very rare, the association of Hyperlipoprotenemia (a) with Sjogrens syndrome and Vasculitis in autoimmune inflammatory arthritis does exist, and the incidence is more in rheumatoid arthritis when compared to SLE, MCTD, Scleroderma and Psoriatic arthritis.
